Objective: Plerixafor is a highly effective mobilization agent in cases of mobilization failure. We aimed to clarify whether earlyadministration of plerixafor after stem cell collection failure results in outcomes similar to those achieved with later administration.Patients and Methods: Sixty-six autologous stem cell transplantation patients who received plerixafor for mobilization failure wereincluded in the study.
Patients were divided into two groups; patients receiving early plerixafor [receiving granulocyte-colonystimulation factor (G-CSF) for 2 or 3 days] and standard plerixafor (receiving G-CSF for 4 days). Both groups were evaluated in termsof neutrophil and platelet engraftment time, CD34 stem cell levels, and side effects.Results: There was no significant difference between the two groups—early plerixafor and standard plerixafor—in terms of neutrophiland platelet engraftment times, CD34⁺ stem cell counts, and adverse effects (CD34/p = 0.201; neutrophil/p = 0.415; platelet/p =0.077; adverse effects/p = 0.439).
No differences were observed between the groups regarding age, gender, transplant type, plerixaforpreparation, adverse effects, or transplant conditioning regimen. Additionally, there was no difference in transplant conditioningregimen between surviving and deceased patients.Conclusion: While the use of G-CSF alone is routine in stem cell mobilization, the addition of plerixafor is preferred in cases ofmobilization failure.
Although chemotherapy-based mobilization is included in mobilization schemes, its use is very limited today. Itwas concluded that plerixafor is a highly effective agent for mobilization, can be used safely in cases of failure in stem cell collection,and that its early use in patients with insufficient reserve may be more cost-effective.